News

In a rare move, pharmaceutical manufacturers voluntarily recalled their drug to treat multiple sclerosis after reports of serious brain inflammation in patients.

The first radioactive drug to treat a certain type of cancer is among the top 3 new drug approvals for cancer. Here are the other top cancer drug approvals so far in 2018.

Biologics, early treatment, and lifestyle choices take the spotlight in rheumatoid arthritis advances.

Reducing hospital readmissions requires just the right mix of clinical expertise and predictive analytics. Here are two health systems that are hitting their stride.

Your net promoter score could be influencing your business. Here’s what it is and how to improve it.

A lack of national standards and less than optimal oversight of many inpatient, opioid addiction rehabilitation programs is raising questions about the level of services, personnel, and quality of care many patients are receiving.

Genetic testing is playing a growing role in diagnosing and treating diseases, particularly when it comes to certain cancers and rheumatic conditions.

Switzerland-based pharma company Roche’s $1.9 billion purchase of tech company Flatiron Health signifies Big Pharma’s need for data.

Successful CAR T-cell therapy reimbursement begins with careful payer-provider collaboration and taking these two approaches.

Eye-opening research by NTT DATA Services sheds light on healthcare consumer satisfaction with virtual versus human agents.

Is your organization on pace with the biggest healthcare technology trends? Here’s your chance to find out.

Hospitals are always looking for ways to reduce readmission rates. They may have an unusual ally in a quality control system originally developed in Europe for the manufacturing sector. Read more about it.

A study from Human Rights Watch has eye-opening findings about antipsychotic drug prescribing in U.S. nursing homes.

Managed care organizations are looking for new skills in healthcare leaders (and in some cases hiring for completely new leadership roles). Here are four emerging trends to watch.

We asked the Managed Healthcare Executive board to share their favorite app-for work or for play. Here’s what they said.

Anthem’s decision has sparked criticism and concern, but could it reduce healthcare spending? Experts weigh in.

Retail drug chain giant Walgreens made a takeover approach to drug distributor AmerisourceBergen. Here’s what industry watchers want you to know about it.

A new survey from Sage Growth Partners offers new ideas on executives’ application and adoption of telemedicine technology.

FDA should provide better education about biosimilar drugs on the agency’s web site dedicated to biosimilars, a patient advocacy group said.

FDA recently approved 3 major drugs to treat lung cancer, prostate cancer, and cystic fibrosis. Here are the top 3 new drug approvals.

A new study has eye-opening findings on the use of buprenorphine induction in an opioid-dependent population with commercial benefit coverage

A coalition is pushing for interoperability advances that it believes could help curb the opioid epidemic. Here’s what it is fighting for.

The landscape of data exchange efficiency continues to be uneven, with some healthcare organizations communicating more proficiently than others. These are the ones struggling the most.

In the year ahead, we can expect to see an insurgence in technology solutions that address patient engagement, data, and security throughout the healthcare system.

John R. Washlick, Buchanan, Ingersoll & Rooney, and expert in healthcare system transactions and market consolidation, talks to Managed Healthcare Executive about healthcare spin-offs, what that means for the future of mergers and acquisitions, and advice for healthcare executives.

Survey reveals why 2018 will be the year for telemedicine

A new report reveals the top cities that rise to the top for healthcare-and they’re probably not the cities you’d expect.

A pharmacist organization is among the supporters of a new Medicare Part D proposal, which calls for a 7-day supply limit on opioid prescriptions.